Stay updated on Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate Clinical Trial

Sign up to get notified when there's something new on the Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The page shows Revision: v3.5.4, replacing the previous Revision: v3.5.3. This indicates a newer version of the page has been published.
    Difference
    0.0%
    Check dated 2026-05-15T15:28:46.000Z thumbnail image
  2. Check
    8 days ago
    No Change Detected
  3. Check
    15 days ago
    No Change Detected
  4. Check
    22 days ago
    Change Detected
    Summary
    The page’s revision/version indicator was updated from v3.5.2 to v3.5.3, reflecting a maintenance or release update rather than a change to the study information.
    Difference
    0.0%
    Check dated 2026-04-24T06:27:36.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    Revision updated from v3.5.0 to v3.5.2.
    Difference
    0.0%
    Check dated 2026-04-17T02:42:54.000Z thumbnail image
  6. Check
    44 days ago
    Change Detected
    Summary
    Added Small cell lung carcinoma as a condition tag and introduced a Resources section linking Genetic and Rare Diseases Information Center.
    Difference
    0.1%
    Check dated 2026-04-02T15:35:48.000Z thumbnail image
  7. Check
    58 days ago
    Change Detected
    Summary
    Site revision updated from v3.4.3 to v3.5.0.
    Difference
    0.0%
    Check dated 2026-03-19T06:19:35.000Z thumbnail image
  8. Check
    66 days ago
    Change Detected
    Summary
    Revision label updated from v3.4.2 to v3.4.3 on the page; this reflects a backend/UI update and does not modify study data or content.
    Difference
    0.0%
    Check dated 2026-03-12T02:46:29.000Z thumbnail image

Stay in the know with updates to Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate Clinical Trial page.